Glioblastoma Clinical Trial Landscape
Data updated: May 20, 2026
964 clinical trials tracked since 2008
Glioblastoma is an aggressive type of cancer that occurs in the brain or spinal cord. As the most common malignant primary brain tumor in adults, it represents a significant area of unmet medical need. The clinical trial landscape for glioblastoma is active, with 966 trials registered since 2008, and 354 currently active. Activity is concentrated in early-phase trials, with 195 active Phase 1 and 208 active Phase 2 trials, compared to 31 active Phase 3 trials. This suggests a strong focus on early-stage investigation of novel therapeutic approaches. Industry sponsorship is distributed across multiple organizations, with Novartis and Philogen S.p.A. each sponsoring 3 active trials. Telix Pharmaceuticals (Innovations) Pty Limited, Cantex Pharmaceuticals, and GT Medical Technologies, Inc. are also active sponsors, each with 2 ongoing trials. The relatively small number of Phase 4 trials (4 active) suggests a limited number of therapies progressing to confirmatory studies and real-world evidence generation.
351 active
/
964 total (since 2008)
194
Phase 1 Active
533 total
205
Phase 2 Active
550 total
30
Phase 3 Active
63 total
4
Phase 4 Active
8 total
Top Industry Sponsors
Sorted by active Active Done Failed
Novartis 3 5 3
GT Medical Technologies, Inc. 2 0 1
Philogen S.p.A. 2 0 1
Telix Pharmaceuticals (Innovations) Pty Limited 2 1 0
Cantex Pharmaceuticals 2 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT03970447 RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research n=2,250
NCT05095376 ACTIVE NOT RECRUITING
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology n=265
NCT06556563 RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NovoCure GmbH n=741
NCT07195591 RECRUITING
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GT Medical Technologies, Inc. n=766
NCT02152982 ACTIVE NOT RECRUITING
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI) n=447
+ 58 more Phase 3 trials — see full database below
Glioblastoma — Trials Started by Year (last 10 years)
2016 55
2017 51
2018 67
2019 42
2020 48
2021 35
2022 59
2023 60
2024 63
2025 63
2026 45
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Novartis 11
GT Medical Technologies, Inc. 3
Philogen S.p.A. 3
Telix Pharmaceuticals (Innovations) Pty Limited 3
Cantex Pharmaceuticals 3
Beijing Biotech 2
NaviFUS Corporation 2
Neonc Technologies, Inc. 2
Jazz Pharmaceuticals 3
Oblato, Inc. 3
Active Trials by Phase
Phase 1 194
Phase 2 205
Phase 3 30
Phase 4 4
Enrollment Size Distribution
1-50 589
51-200 267
201-500 38
501-1k 18
1k+ 1
All Industry Sponsors
Sorted by active Active Done Failed
Novartis 3 5 3
GT Medical Technologies, Inc. 2 0 1
Philogen S.p.A. 2 0 1
Telix Pharmaceuticals (Innovations) Pty Limited 2 1 0
Cantex Pharmaceuticals 2 1 0
Beijing Biotech 2 0 0
NaviFUS Corporation 2 0 0
Neonc Technologies, Inc. 2 0 0
Jazz Pharmaceuticals 1 0 2
Oblato, Inc. 1 1 1
TVAX Biomedical 1 2 0
NovoCure GmbH 1 1 0
CarThera 1 1 0
Jecho Biopharmaceuticals Co., Ltd. 1 1 0
ImmunityBio, Inc. 1 1 0
NCT03970447 RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research n=2,250
NCT05095376 ACTIVE NOT RECRUITING
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology n=265
NCT07452458 NOT YET RECRUITING
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NRG Oncology n=398
NCT06556563 RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NovoCure GmbH n=741
NCT07195591 RECRUITING
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GT Medical Technologies, Inc. n=766
NCT02152982 ACTIVE NOT RECRUITING
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI) n=447
NCT05902169 RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
CarThera n=560
NCT07100730 RECRUITING
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited n=50
NCT06419946 RECRUITING
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region n=200
NCT06496971 RECRUITING
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation n=32
NCT06388733 RECRUITING
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center n=450
NCT03663725 ACTIVE NOT RECRUITING
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Centre Oscar Lambret n=486
NCT07461948 RECRUITING
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Jonsson Comprehensive Cancer Center n=15
NCT06448286 NOT YET RECRUITING
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center n=60
NCT05904119 RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
European Organisation for Research and Treatment of Cancer - EORTC n=411
NCT06105619 ACTIVE NOT RECRUITING
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company n=84
NCT07349693 NOT YET RECRUITING
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Everfront Biotech Co., Ltd. n=175
NCT05326464 ACTIVE NOT RECRUITING
Tofacitinib in Recurrent GBM Patients
University of Texas Southwestern Medical Center n=17
NCT04250922 ACTIVE NOT RECRUITING
LAM561 With RT and TMZ for Adults With Glioblastoma
Laminar Pharmaceuticals n=144
NCT02685605 ACTIVE NOT RECRUITING
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Universitätsmedizin Mannheim n=314
NCT05685004 ACTIVE NOT RECRUITING
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
TVAX Biomedical n=120
NCT07021339 RECRUITING
Anterior Temporal Lobectomy in Temporal Glioblastoma
University Hospital, Bonn n=178
NCT05439278 RECRUITING
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Severance Hospital n=178
NCT06749925 NOT YET RECRUITING
Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma
University of Sao Paulo General Hospital n=186
NCT05118776 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharmaceuticals Co., Ltd. n=136
NCT05271240 RECRUITING
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health n=432
NCT06477939 NOT YET RECRUITING
Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients
Institut de cancérologie Strasbourg Europe n=554
NCT05318612 ACTIVE NOT RECRUITING
Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)
Radboud University Medical Center n=238
NCT05100641 NOT YET RECRUITING
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
Aivita Biomedical, Inc. n=672
NCT04105374 WITHDRAWN
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
NCT04396860 COMPLETED
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI) n=159
NCT01507506 TERMINATED
Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma
Institut Claudius Regaud n=180
NCT00807027 COMPLETED
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
GC Cell Corporation n=180
NCT01811121 COMPLETED
MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS
Hospices Civils de Lyon n=170
NCT03149575 TERMINATED
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
DelMar Pharmaceuticals, Inc. n=2
NCT03345095 COMPLETED
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC n=749
NCT03632135 COMPLETED
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
Cordgenics, LLC n=78
NCT02017717 COMPLETED
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Bristol-Myers Squibb n=529
NCT03776071 COMPLETED
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC n=260
NCT02546102 SUSPENDED
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Precision Life Sciences Group n=234
NCT03149003 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc. n=221
NCT05718466 COMPLETED
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System n=35
NCT02573324 COMPLETED
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
AbbVie n=691
NCT03291977 COMPLETED
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Rennes University Hospital n=51
NCT03393000 TERMINATED
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Diffusion Pharmaceuticals Inc n=19
NCT01290939 COMPLETED
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC n=592
NCT01805453 COMPLETED
Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
Assistance Publique - Hôpitaux de Paris n=80
NCT02414165 TERMINATED
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Tocagen Inc. n=403
NCT00884741 COMPLETED
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI) n=637
NCT02511405 COMPLETED
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Vascular Biogenics Ltd. operating as VBL Therapeutics n=252
NCT01480479 COMPLETED
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Celldex Therapeutics n=745
NCT00943826 COMPLETED
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche n=921
NCT01149109 COMPLETED
Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
University Hospital, Bonn n=141
NCT00916409 COMPLETED
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NovoCure Ltd. n=700
NCT00777153 COMPLETED
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
AstraZeneca n=423
NCT01830101 WITHDRAWN
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
AHS Cancer Control Alberta
NCT01450449 COMPLETED
Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme
International Atomic Energy Agency n=115
NCT00761280 TERMINATED
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Isarna Therapeutics GmbH n=27
NCT00689221 COMPLETED
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
EMD Serono n=545
NCT00615186 TERMINATED
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Bradmer Pharmaceuticals Inc. n=9
NCT05864534 RECRUITING
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
NCT03919071 ACTIVE NOT RECRUITING
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
NCT05432804 RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
NCT06161519 RECRUITING
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Cancer Institute (NCI)
NCT07416188 RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institute of Neurological Disorders and Stroke (NINDS)
NCT07326566 RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
NCT07003542 RECRUITING
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Case Comprehensive Cancer Center
NCT02331498 ACTIVE NOT RECRUITING
Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Centre Antoine Lacassagne
NCT06319027 RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
ECOG-ACRIN Cancer Research Group
NCT05708352 RECRUITING
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Cedars-Sinai Medical Center
NCT06804655 NOT YET RECRUITING
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
University of Zurich
NCT06649851 RECRUITING
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital
NCT05629702 RECRUITING
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
University of Birmingham
NCT03491683 ACTIVE NOT RECRUITING
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
NCT04145115 ACTIVE NOT RECRUITING
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
NCT03581292 ACTIVE NOT RECRUITING
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
NCT07346144 RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Trogenix ltd
NCT05933265 ACTIVE NOT RECRUITING
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
NCT07297212 RECRUITING
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
NCT05765812 RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT04922723 ACTIVE NOT RECRUITING
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
West Virginia University
NCT05565521 ACTIVE NOT RECRUITING
UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
Sunnybrook Health Sciences Centre
NCT06805305 RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
NCT05843253 RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT06069726 RECRUITING
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Duke University
NCT06336291 ACTIVE NOT RECRUITING
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Philogen S.p.A.
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT04762069 ACTIVE NOT RECRUITING
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
NCT06607692 RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Fundación de investigación HM
NCT07185880 RECRUITING
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Myosin Therapeutics Inc.
NCT04528680 ACTIVE NOT RECRUITING
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT02800486 RECRUITING
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT07468136 NOT YET RECRUITING
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
NCT06810544 RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
NCT06329570 RECRUITING
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
NCT03277638 ACTIVE NOT RECRUITING
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
NCT07301268 RECRUITING
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
NCT07511725 RECRUITING
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04729959 ACTIVE NOT RECRUITING
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT05986851 ACTIVE NOT RECRUITING
Azeliragon in MGMT Unmethylated Glioblastoma
Cantex Pharmaceuticals
NCT07501559 RECRUITING
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Jecho Biopharmaceuticals Co., Ltd.
NCT04559230 RECRUITING
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT03596086 RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
David Baskin MD
NCT07431216 NOT YET RECRUITING
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Starlight Therapeutics Inc.
NCT02455557 ACTIVE NOT RECRUITING
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
NCT03603405 RECRUITING
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
NCT04574856 ACTIVE NOT RECRUITING
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
NCT02586857 ACTIVE NOT RECRUITING
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
NCT03197506 ACTIVE NOT RECRUITING
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
NCT07392957 NOT YET RECRUITING
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
Washington University School of Medicine
NCT07225621 RECRUITING
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
NCT07476794 RECRUITING
Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma
Sunnybrook Health Sciences Centre
NCT06926075 RECRUITING
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Filamon LTD
NCT06504381 RECRUITING
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
NCT05463848 RECRUITING
Surgical Pembro +/- Olaparib w TMZ for rGBM
L. Nicolas Gonzalez Castro, MD, PhD
NCT05607407 RECRUITING
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT02704858 RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
NCT07439172 NOT YET RECRUITING
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
The Cooper Health System
NCT06672575 RECRUITING
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT06058988 RECRUITING
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06622434 RECRUITING
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Assistance Publique - Hôpitaux de Paris
NCT03212274 ACTIVE NOT RECRUITING
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT07318818 RECRUITING
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Tasly Pharmaceutical Group Co., Ltd
NCT07263438 RECRUITING
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Centre Hospitalier Universitaire Vaudois
NCT04765514 RECRUITING
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
AHS Cancer Control Alberta
NCT06061809 RECRUITING
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
NCT04485949 ACTIVE NOT RECRUITING
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
NCT07386002 NOT YET RECRUITING
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
T-MAXIMUM Pharmaceutical Inc
NCT04478279 ACTIVE NOT RECRUITING
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT03866109 ACTIVE NOT RECRUITING
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Genenta Science
NCT03405792 ACTIVE NOT RECRUITING
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
University of Florida
NCT05635734 ACTIVE NOT RECRUITING
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Cantex Pharmaceuticals
NCT07389278 NOT YET RECRUITING
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Sabine Mueller, MD, PhD
NCT07391215 RECRUITING
5G-PEARL: Paxalisib in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT05653622 RECRUITING
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Centre Paul Strauss
NCT05653635 RECRUITING
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Centre Paul Strauss
NCT05781321 ACTIVE NOT RECRUITING
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Mayo Clinic
NCT05683808 RECRUITING
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
NCT04752813 ACTIVE NOT RECRUITING
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
NCT07365280 NOT YET RECRUITING
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
NCT07356973 NOT YET RECRUITING
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
CRISM Therapeutics LTD
NCT07364786 RECRUITING
Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
Peter Siesjö
NCT05084430 RECRUITING
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
NCT06630260 RECRUITING
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT07347210 NOT YET RECRUITING
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Centre Hospitalier Universitaire de Besancon
NCT02179086 ACTIVE NOT RECRUITING
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NRG Oncology
NCT04623931 RECRUITING
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT05465954 RECRUITING
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
NCT05871021 RECRUITING
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
University Hospital Tuebingen
NCT06816927 RECRUITING
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Duke University
NCT04049669 ACTIVE NOT RECRUITING
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Theodore S. Johnson
NCT06558214 RECRUITING
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
University of Florida
NCT03743662 ACTIVE NOT RECRUITING
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT07093814 RECRUITING
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT05879250 RECRUITING
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT06991101 RECRUITING
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT04116411 ACTIVE NOT RECRUITING
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
Cecilia Soderberg-Naucler
NCT04691960 ACTIVE NOT RECRUITING
A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
Weill Medical College of Cornell University
NCT05039281 RECRUITING
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT02177578 ACTIVE NOT RECRUITING
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02344355 ACTIVE NOT RECRUITING
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Bryan Allen
NCT05956821 RECRUITING
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT03718767 ACTIVE NOT RECRUITING
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT04945148 RECRUITING
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Hopital Foch
NCT03233152 ACTIVE NOT RECRUITING
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
Universitair Ziekenhuis Brussel
NCT06521567 ACTIVE NOT RECRUITING
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT02977780 RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
NCT04373785 NOT YET RECRUITING
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
NCT03862430 ACTIVE NOT RECRUITING
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NuvOx LLC
NCT06059690 RECRUITING
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Jonsson Comprehensive Cancer Center
NCT06011109 RECRUITING
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
NCT07193654 RECRUITING
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07180927 RECRUITING
DLL3 CAR-T Therapy Targeting Brain Tumors
Shenzhen Geno-Immune Medical Institute
NCT06835803 RECRUITING
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
Brigham and Women's Hospital
NCT06492486 NOT YET RECRUITING
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Tata Memorial Centre
NCT05736406 RECRUITING
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
NCT06102525 RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Rznomics, Inc.
NCT04977375 RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Chirag G. Patil
NCT02981940 ACTIVE NOT RECRUITING
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
NCT05120284 ACTIVE NOT RECRUITING
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
University of Florida
NCT04863950 RECRUITING
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT04587830 ACTIVE NOT RECRUITING
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
Polaris Group
NCT07138001 NOT YET RECRUITING
Phase 2 Clinical Trial of KH617
Sichuan Honghe Biotechnology Co., Ltd.
NCT04747145 ACTIVE NOT RECRUITING
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
Medical College of Wisconsin
NCT04910022 ACTIVE NOT RECRUITING
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
NCT06018363 RECRUITING
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Dushu Lake Hospital Affiliated to Soochow University
NCT07130149 ENROLLING BY INVITATION
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
Yingjuan Zheng
NCT02337686 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT04225039 ACTIVE NOT RECRUITING
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
NCT04469075 ACTIVE NOT RECRUITING
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Memorial Sloan Kettering Cancer Center
NCT06356883 RECRUITING
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
NCT02974621 ACTIVE NOT RECRUITING
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT05929495 RECRUITING
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
University of Milano Bicocca
NCT04523688 RECRUITING
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT05909618 RECRUITING
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Sheba Medical Center
NCT07047066 NOT YET RECRUITING
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
Tongji Hospital
NCT03175224 RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT02780024 ACTIVE NOT RECRUITING
Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT04765098 RECRUITING
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
NCT04121455 ACTIVE NOT RECRUITING
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
TME Pharma AG
NCT04019262 ACTIVE NOT RECRUITING
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
John Flickinger
NCT01777919 NOT YET RECRUITING
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Olympion Medical Center
NCT03897491 ACTIVE NOT RECRUITING
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
photonamic GmbH & Co. KG
NCT03673787 ACTIVE NOT RECRUITING
A Trial of Ipatasertib in Combination With Atezolizumab
Institute of Cancer Research, United Kingdom
NCT06598787 RECRUITING
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05664243 ACTIVE NOT RECRUITING
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
NCT06936046 RECRUITING
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03688178 ACTIVE NOT RECRUITING
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Annick Desjardins, MD
NCT06016452 RECRUITING
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
Tata Memorial Centre
NCT06687681 RECRUITING
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Marzieh Ebrahimi
NCT02861898 RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
NCT01269853 RECRUITING
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Northwell Health
NCT03213002 RECRUITING
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT06690216 ENROLLING BY INVITATION
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
Man Hu
NCT01903330 ACTIVE NOT RECRUITING
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
NCT03452579 ACTIVE NOT RECRUITING
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
David Peereboom
NCT04590664 RECRUITING
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
NCT04881032 ACTIVE NOT RECRUITING
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
Centre Jean Perrin
NCT06780592 NOT YET RECRUITING
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
Huashan Hospital
NCT05590689 RECRUITING
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Universität Münster
NCT04195139 ACTIVE NOT RECRUITING
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
University of Sydney
NCT03395587 ACTIVE NOT RECRUITING
Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
Heinrich-Heine University, Duesseldorf
NCT05768919 RECRUITING
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
SignPath Pharma, Inc.
NCT06160206 RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
NCT06640582 RECRUITING
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Essen Biotech
NCT01985087 ACTIVE NOT RECRUITING
A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
University of Louisville
NCT04267978 RECRUITING
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06595186 RECRUITING
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
NCT02649582 ACTIVE NOT RECRUITING
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
University Hospital, Antwerp
NCT04115761 RECRUITING
Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Ever Supreme Bio Technology Co., Ltd.
NCT06157541 RECRUITING
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Queensland Institute of Medical Research
NCT03899857 ACTIVE NOT RECRUITING
Pembrolizumab for Newly Diagnosed Glioblastoma
University of Zurich
NCT06327451 RECRUITING
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Tianjin Medical University General Hospital
NCT06297512 RECRUITING
Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).
Iacopo Sardi
NCT06220552 RECRUITING
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University
NCT06218524 NOT YET RECRUITING
The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM
Southern Medical University, China
NCT05820191 NOT YET RECRUITING
B-amyloid as a Marker for GBM Bioimaging
Universidad Central del Caribe
NCT04443010 RECRUITING
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Philogen S.p.A.
NCT05540275 NOT YET RECRUITING
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
NCT05842746 NOT YET RECRUITING
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
Peking Union Medical College Hospital
NCT05502991 NOT YET RECRUITING
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
NCT06325683 SUSPENDED
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03382977 TERMINATED
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
NCT03797326 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Merck Sharp & Dohme LLC
NCT06894225 SUSPENDED
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
National Neuroscience Institute
NCT04817254 COMPLETED
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT02866747 COMPLETED
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
Institut Claudius Regaud
NCT04801147 COMPLETED
Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT04417088 COMPLETED
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
NCT05753007 TERMINATED
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
NCT03475186 COMPLETED
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
NCT02942264 TERMINATED
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Cancer Institute (NCI)
NCT03529448 COMPLETED
TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
NCT04482933 WITHDRAWN
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
NCT04440358 COMPLETED
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
NCT02617745 COMPLETED
Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid
Centre Henri Becquerel
NCT05267106 TERMINATED
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Incyte Corporation
NCT06359379 TERMINATED
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
NCT05183204 SUSPENDED
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Weill Medical College of Cornell University
NCT04391062 COMPLETED
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
University Hospital, Lille
NCT04116658 COMPLETED
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
Enterome
NCT03532295 COMPLETED
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
NCT03746080 COMPLETED
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Lawrence D Recht
NCT06855628 SUSPENDED
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Stanford University
NCT03868943 TERMINATED
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
Wake Forest University Health Sciences
NCT06439420 COMPLETED
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Virginia Commonwealth University
NCT05608395 COMPLETED
11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
Masaryk Memorial Cancer Institute
NCT03174197 COMPLETED
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
NCT03347617 TERMINATED
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
NCT03050736 COMPLETED
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
NCT01478178 COMPLETED
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
NCT02717962 COMPLETED
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
NCT02327078 COMPLETED
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
NCT07120620 COMPLETED
PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma
Sied Kebir
NCT04388475 COMPLETED
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
NCT01931098 COMPLETED
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Cancer Institute (NCI)
NCT03018288 TERMINATED
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Cancer Institute (NCI)
NCT03137888 COMPLETED
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
NCT05563272 TERMINATED
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT03778294 COMPLETED
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
NCT02781792 COMPLETED
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
NCT04740190 COMPLETED
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
The University of Hong Kong
NCT04406272 TERMINATED
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
NCT02655601 COMPLETED
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
BioMimetix JV, LLC
NCT04479241 COMPLETED
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
NCT04051606 COMPLETED
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT03047473 COMPLETED
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Clinique Neuro-Outaouais
NCT03782415 COMPLETED
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
NCT03665545 COMPLETED
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
University Hospital, Geneva
NCT04006119 TERMINATED
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Alaunos Therapeutics
NCT02715609 COMPLETED
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT01386710 SUSPENDED
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Northwell Health
NCT03522298 COMPLETED
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
NCT04469699 TERMINATED
Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
University Hospital Muenster
NCT05737212 TERMINATED
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
NCT01894061 COMPLETED
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT02078648 COMPLETED
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
NCT01814813 TERMINATED
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
NCT03914742 COMPLETED
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02465268 COMPLETED
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
University of Florida
NCT04280848 COMPLETED
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Centre Hospitalier Universitaire de Besancon
NCT06328036 WITHDRAWN
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04421378 TERMINATED
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
NCT01464177 COMPLETED
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Andre Tsin Chih Chen
NCT01291420 COMPLETED
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
NCT05973903 WITHDRAWN
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Tel Aviv Medical Center
NCT05879120 WITHDRAWN
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT03732352 COMPLETED
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT04845919 COMPLETED
Sonodynamic Therapy With ExAblate System in Glioblastoma Patients
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT02372409 TERMINATED
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
NCT03973918 TERMINATED
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04952571 TERMINATED
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Beijing Sanbo Brain Hospital
NCT03363659 TERMINATED
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
Wake Forest University Health Sciences
NCT03879512 COMPLETED
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
NCT03234595 COMPLETED
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
NCT01149850 COMPLETED
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
NCT03661723 COMPLETED
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
NCT01204684 COMPLETED
Dendritic Cell Vaccine for Patients With Brain Tumors
Jonsson Comprehensive Cancer Center
NCT04013672 COMPLETED
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
David Peereboom
NCT06562621 COMPLETED
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
NCT04492163 COMPLETED
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
NovoCure GmbH
NCT05370508 TERMINATED
A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
SonALAsense, Inc.
NCT01817751 COMPLETED
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Virginia Commonwealth University
NCT01837862 COMPLETED
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT04915404 TERMINATED
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
WPD Pharmaceuticals Sp. z o.o.
NCT02014844 COMPLETED
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
NCT02067156 COMPLETED
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
GenSpera, Inc.
NCT01591577 COMPLETED
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
NCT03139916 COMPLETED
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
NCT01622764 WITHDRAWN
89Zr-RO5323441 PET Imaging in Glioblastoma
University Medical Center Groningen
NCT05074992 TERMINATED
A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
University College, London
NCT04681677 TERMINATED
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
Xoft, Inc.
NCT02085304 TERMINATED
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
St. Joseph's Hospital and Medical Center, Phoenix
NCT03927222 TERMINATED
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT03466450 COMPLETED
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
NCT02052648 COMPLETED
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
NewLink Genetics Corporation
NCT02206230 COMPLETED
Trial of Hypofractionated Radiation Therapy for Glioblastoma
AHS Cancer Control Alberta
NCT01811498 COMPLETED
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Northwell Health
NCT02684058 COMPLETED
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis Pharmaceuticals
NCT04629209 WITHDRAWN
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
NCT03027388 COMPLETED
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03684811 COMPLETED
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT02432417 WITHDRAWN
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Maastricht Radiation Oncology
NCT02315534 COMPLETED
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
NCT03463265 COMPLETED
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Aadi Bioscience, Inc.
NCT04119674 COMPLETED
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
Zhejiang Cancer Hospital
NCT01259869 COMPLETED
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
NCIC Clinical Trials Group
NCT02330991 COMPLETED
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
NCT01290692 COMPLETED
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
NCT02661282 COMPLETED
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
NCT02366728 COMPLETED
DC Migration Study for Newly-Diagnosed GBM
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT00662506 COMPLETED
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT01081223 COMPLETED
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
NCT04933942 WITHDRAWN
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT01721577 TERMINATED
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
Rush University Medical Center
NCT03618667 COMPLETED
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Samsung Medical Center
NCT03849105 COMPLETED
131I-IPA and Concurrent XRT in Recurrent GBM
Telix Pharmaceuticals (Innovations) Pty Limited
NCT01933815 SUSPENDED
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
NCT05218408 WITHDRAWN
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Celularity Incorporated
NCT03430791 TERMINATED
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
NCT01986348 TERMINATED
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
Karyopharm Therapeutics Inc
NCT04657315 COMPLETED
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
CHA University
NCT01730950 COMPLETED
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
NCT01822275 TERMINATED
Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
University of Maryland, Baltimore
NCT04444427 COMPLETED
Evaluation of GLR2007 for Advanced Solid Tumors
Gan and Lee Pharmaceuticals, USA
NCT01177397 COMPLETED
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT03119064 TERMINATED
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
Brown University
NCT01301430 COMPLETED
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
Oryx GmbH & Co. KG
NCT02858895 COMPLETED
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
NCT02336165 COMPLETED
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Ludwig Institute for Cancer Research
NCT03649464 WITHDRAWN
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
NCT02885324 TERMINATED
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Indiana University
NCT00687765 COMPLETED
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Sanofi
NCT03744026 COMPLETED
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
CarThera
NCT03856099 TERMINATED
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
PharmAbcine
NCT02302235 COMPLETED
Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study
Mid-Atlantic Epilepsy and Sleep Center, LLC
NCT03022578 TERMINATED
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
M.D. Anderson Cancer Center
NCT01884740 TERMINATED
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
NCT00731731 COMPLETED
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT01062425 COMPLETED
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT01609790 COMPLETED
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT03367715 COMPLETED
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
NYU Langone Health
NCT02968940 COMPLETED
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
NYU Langone Health
NCT02663271 TERMINATED
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
NCT02330562 COMPLETED
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
NCT01434602 COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT00669669 TERMINATED
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
NCT03216499 COMPLETED
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02794883 COMPLETED
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
NCT01004874 COMPLETED
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
NCT02750891 COMPLETED
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Sumitomo Pharma Co., Ltd.
NCT04065087 WITHDRAWN
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Genexine, Inc.
NCT00805961 COMPLETED
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
NCT01856933 COMPLETED
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Heinrich Elinzano, MD
NCT01587144 TERMINATED
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
Spectrum Pharmaceuticals, Inc
NCT02770378 COMPLETED
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
NCT02844439 COMPLETED
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
NCT03034135 COMPLETED
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
NCT03243851 COMPLETED
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
Yong-Kil Hong
NCT01110876 TERMINATED
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
NCT01631552 COMPLETED
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
NCT01120639 COMPLETED
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Stanford University
NCT02765165 TERMINATED
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
NCT00879437 COMPLETED
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
NCT01051557 COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
NCT02798406 COMPLETED
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
DNAtrix, Inc.
NCT01520870 COMPLETED
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
NCT02046187 TERMINATED
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
St. Joseph's Hospital and Medical Center, Phoenix
NCT02743078 TERMINATED
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
NCT02038699 WITHDRAWN
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
NCT02340156 TERMINATED
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
SynerGene Therapeutics, Inc.
NCT02758366 TERMINATED
Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
Meyer Children's Hospital IRCCS
NCT03033524 COMPLETED
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
PharmAbcine
NCT02296476 TERMINATED
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02209948 COMPLETED
Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
Grupo Español de Investigación en Neurooncología
NCT02709889 TERMINATED
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT03506139 WITHDRAWN
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
John M. Buatti
NCT03014804 WITHDRAWN
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT02626364 COMPLETED
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Arog Pharmaceuticals, Inc.
NCT01790503 COMPLETED
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
NCT01349660 COMPLETED
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
SCRI Development Innovations, LLC
NCT02343406 COMPLETED
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
AbbVie
NCT02799238 COMPLETED
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
CytoVac A/S
NCT01260506 COMPLETED
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Vascular Biogenics Ltd. operating as VBL Therapeutics
NCT02342379 COMPLETED
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT01067469 COMPLETED
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
NCT01478321 TERMINATED
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
NCT01349036 TERMINATED
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
Daiichi Sankyo
NCT01402063 COMPLETED
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Brown University
NCT01498328 COMPLETED
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Celldex Therapeutics
NCT01392352 TERMINATED
HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT02754362 WITHDRAWN
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
NCT02335918 COMPLETED
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Celldex Therapeutics
NCT01975701 COMPLETED
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Novartis Pharmaceuticals
NCT00984438 WITHDRAWN
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
NCT01756352 COMPLETED
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
Marcelo F. Di Carli, MD, FACC
NCT01989884 COMPLETED
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
Mario Negri Institute for Pharmacological Research
NCT00892177 COMPLETED
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
NCT01806675 COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Sanjiv Sam Gambhir
NCT01454596 COMPLETED
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Cancer Institute (NCI)
NCT02364206 COMPLETED
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Centre Jean Perrin
NCT01514201 COMPLETED
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
National Cancer Institute (NCI)
NCT01564914 COMPLETED
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Tracon Pharmaceuticals Inc.
NCT02120287 COMPLETED
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
Ajay Niranjan
NCT01209442 COMPLETED
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
University of Colorado, Denver
NCT00961090 COMPLETED
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Matthew R Quigley
NCT00902577 COMPLETED
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT02395692 TERMINATED
Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT01339052 COMPLETED
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Patrick Y. Wen, MD
NCT01186406 TERMINATED
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
NCT01044966 TERMINATED
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Medical University of South Carolina
NCT01562197 COMPLETED
A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Bart Neyns
NCT03291314 COMPLETED
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel
NCT01977677 COMPLETED
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Lawrence Recht
NCT02850744 TERMINATED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
PIQUR Therapeutics AG
NCT02253212 COMPLETED
Safety of BBB Opening With the SonoCloud
Assistance Publique - Hôpitaux de Paris
NCT01112527 COMPLETED
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
NCT00679354 COMPLETED
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
National Cancer Institute (NCI)
NCT01266031 COMPLETED
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT01575275 TERMINATED
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Michael Vogelbaum, MD, PhD
NCT02698280 COMPLETED
Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Huashan Hospital
NCT02478164 COMPLETED
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
NCT01836549 TERMINATED
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
NCT01870726 TERMINATED
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis Pharmaceuticals
NCT01648348 COMPLETED
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT02157103 COMPLETED
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Emory University
NCT01602588 COMPLETED
A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
University College, London
NCT01860638 COMPLETED
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
NCT02227576 TERMINATED
Prevention of Thrombocytopenia in Glioblastoma Patients
University Hospital, Lille
NCT02654041 TERMINATED
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Musli Thyropeutics Ltd.
NCT01788280 WITHDRAWN
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
University of Utah
NCT01632228 COMPLETED
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Hoffmann-La Roche
NCT02047214 TERMINATED
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
NCT01782976 WITHDRAWN
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
NCT02348255 WITHDRAWN
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
University of California, Davis
NCT03388372 COMPLETED
Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
Biotech Pharmaceutical Co., Ltd.
NCT00895180 COMPLETED
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01753713 COMPLETED
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Manmeet Ahluwalia, MD
NCT01866449 COMPLETED
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
University of Ulm
NCT03310372 COMPLETED
Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
Central Hospital, Nancy, France
NCT01310868 COMPLETED
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
University College, London
NCT01508117 TERMINATED
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
University of Cincinnati
NCT02029573 COMPLETED
Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
King Fahad Medical City
NCT00980343 COMPLETED
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT00540722 COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT01465347 COMPLETED
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals Inc
NCT00823797 COMPLETED
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
University of Washington
NCT01413438 WITHDRAWN
Bevacizumab With or Without Surgery for Adult Glioblastomas
National Institute of Neurological Disorders and Stroke (NINDS)
NCT01310855 TERMINATED
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
NCT01122901 TERMINATED
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
NCT02550249 COMPLETED
Neoadjuvant Nivolumab in Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
NCT01268566 COMPLETED
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
MedImmune LLC
NCT00883298 COMPLETED
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Center for Neurosciences, Tucson
NCT01280552 COMPLETED
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Precision Life Sciences Group
NCT01738646 COMPLETED
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Duke University
NCT00813943 COMPLETED
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
EMD Serono
NCT02394665 TERMINATED
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
University of Miami
NCT01443676 COMPLETED
Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
University of Zurich
NCT02104882 COMPLETED
INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study
Universitätsmedizin Mannheim
NCT02898012 COMPLETED
Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status
Assistance Publique - Hôpitaux de Paris
NCT01331291 COMPLETED
Bosutinib in Adult Patients With Recurrent Glioblastoma
Massachusetts General Hospital
NCT02060955 TERMINATED
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
NCT01445691 WITHDRAWN
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Constantinos Hadjipanayis
NCT00995007 COMPLETED
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT01351519 TERMINATED
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
MultiCare Health System Research Institute
NCT01474239 COMPLETED
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Hoffmann-La Roche
NCT02521090 WITHDRAWN
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
NCT01189240 TERMINATED
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
NCT00967330 COMPLETED
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Hoffmann-La Roche
NCT02599090 WITHDRAWN
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT00667394 COMPLETED
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT00846456 COMPLETED
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma
Oslo University Hospital
NCT01898273 TERMINATED
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Cellectar Biosciences, Inc.
NCT01227434 TERMINATED
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
University of California, San Francisco
NCT02474966 COMPLETED
Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study
University of Roma La Sapienza
NCT01174537 WITHDRAWN
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Hadassah Medical Organization
NCT01582516 COMPLETED
Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
Erasmus Medical Center
NCT01115491 COMPLETED
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Hoffmann-La Roche
NCT01006044 COMPLETED
Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection
Clinica Universidad de Navarra, Universidad de Navarra
NCT00941460 COMPLETED
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
Prof. Dr. Wolfgang Wick
NCT00641706 COMPLETED
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT00979017 COMPLETED
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Katy Peters
NCT00611325 COMPLETED
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Duke University
NCT00921167 COMPLETED
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Clinical Research Center for Solid Tumor, Korea
NCT01205334 TERMINATED
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
Baylor College of Medicine
NCT00613028 COMPLETED
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Duke University
NCT00870181 COMPLETED
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Huazhong University of Science and Technology
NCT00939991 COMPLETED
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Katy Peters
NCT01095094 TERMINATED
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Case Comprehensive Cancer Center
NCT01011231 TERMINATED
Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma
University of California, San Francisco
NCT00650949 TERMINATED
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
Gilead Sciences
NCT01100177 COMPLETED
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
Grupo Español de Investigación en Neurooncología
NCT00906893 COMPLETED
Evaluation of [18F]-FMISO for Non Operated Glioblastoma
University Hospital, Bordeaux
NCT00959946 TERMINATED
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
Pfizer
NCT00735436 TERMINATED
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Duke University
NCT00797940 WITHDRAWN
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
Sophiris Bio Corp
NCT01022918 COMPLETED
Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma
Centre Georges Francois Leclerc
NCT00948389 TERMINATED
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Bristol-Myers Squibb
NCT00624728 COMPLETED
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
University Hospital, Bordeaux
NCT01285414 COMPLETED
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
Myrexis Inc.
NCT01044225 TERMINATED
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Bart Neyns
NCT00790452 TERMINATED
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
M.D. Anderson Cancer Center
NCT00817284 COMPLETED
Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
Ulrik Lassen
NCT00715013 COMPLETED
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
University of Zurich
NCT00800917 COMPLETED
A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
Rigshospitalet, Denmark
NCT00730262 TERMINATED
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
Thallion Pharmaceuticals
NCT07422363 NOT YET RECRUITING
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT07579208 NOT YET RECRUITING
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT06973096 RECRUITING
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
University of Pennsylvania
NCT07209241 RECRUITING
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
University of Pennsylvania
NCT02192359 ACTIVE NOT RECRUITING
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT05565118 RECRUITING
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Case Comprehensive Cancer Center
NCT04015700 ACTIVE NOT RECRUITING
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT07544992 RECRUITING
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
City of Hope Medical Center
NCT07343986 RECRUITING
Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
University of Virginia
NCT06894979 RECRUITING
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04003649 ACTIVE NOT RECRUITING
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
NCT05835687 RECRUITING
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT06176066 RECRUITING
PH Sensitive MRI Based Resections of Glioblastoma
University of California, Los Angeles
NCT05241392 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Beijing Tiantan Hospital
NCT05743595 ACTIVE NOT RECRUITING
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT07560865 RECRUITING
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Masonic Cancer Center, University of Minnesota
NCT06410248 RECRUITING
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Northwestern University
NCT07464925 RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
NCT05283330 RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
NCT06389591 RECRUITING
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
University of Florida
NCT02142803 ACTIVE NOT RECRUITING
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
NCT05303467 RECRUITING
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Boston Scientific Corporation
NCT04903795 NOT YET RECRUITING
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT04573140 RECRUITING
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
University of Florida
NCT07551336 RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Beijing Biotech
NCT03170141 ENROLLING BY INVITATION
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Shenzhen Geno-Immune Medical Institute
NCT03383978 RECRUITING
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
Johann Wolfgang Goethe University Hospital
NCT03961971 ACTIVE NOT RECRUITING
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05366179 RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
NCT05917145 RECRUITING
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Mayo Clinic
NCT07541781 NOT YET RECRUITING
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Kailin Yang, MD, PhD
NCT05698524 RECRUITING
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT02287428 ACTIVE NOT RECRUITING
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
NCT05168423 ACTIVE NOT RECRUITING
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
NCT03911388 RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT07134842 RECRUITING
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
University College, London
NCT06344130 RECRUITING
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT07089641 RECRUITING
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Jonsson Comprehensive Cancer Center
NCT04978727 ACTIVE NOT RECRUITING
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT05789394 RECRUITING
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
NCT04197934 ACTIVE NOT RECRUITING
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
NCT06934889 RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT07480941 RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Beijing Biotech
NCT04678648 RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
NCT04732065 RECRUITING
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Sabine Mueller, MD, PhD
NCT05109728 ACTIVE NOT RECRUITING
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis Pharmaceuticals
NCT06186401 RECRUITING
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Hideho Okada, MD, PhD
NCT03749187 ACTIVE NOT RECRUITING
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT05353530 ACTIVE NOT RECRUITING
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
University of Florida
NCT07455045 NOT YET RECRUITING
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT03896568 RECRUITING
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
NCT04661384 ACTIVE NOT RECRUITING
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT03152318 ACTIVE NOT RECRUITING
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
NCT03389802 ACTIVE NOT RECRUITING
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT07422896 NOT YET RECRUITING
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
Catalina Lee Chang
NCT03514069 ACTIVE NOT RECRUITING
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
NCT04606316 ACTIVE NOT RECRUITING
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Patrick Wen, MD
NCT07218367 NOT YET RECRUITING
Phase I Trial of pH Resections of GBM at VA
VA Office of Research and Development
NCT07385846 NOT YET RECRUITING
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Jennifer Leddon
NCT03389230 ACTIVE NOT RECRUITING
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT05739942 ACTIVE NOT RECRUITING
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis Pharmaceuticals
NCT05627323 ACTIVE NOT RECRUITING
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Chimeric Therapeutics
NCT06815432 RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Baylor College of Medicine
NCT04216329 ACTIVE NOT RECRUITING
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT07143812 RECRUITING
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
CHA University
NCT05450744 RECRUITING
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Telix Pharmaceuticals (Innovations) Pty Limited
NCT05236036 ACTIVE NOT RECRUITING
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05083754 RECRUITING
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05106296 RECRUITING
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Theodore S. Johnson
NCT03423628 RECRUITING
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
NCT04541082 RECRUITING
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT05686798 RECRUITING
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT03587038 ACTIVE NOT RECRUITING
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
University of Oklahoma
NCT04900792 ACTIVE NOT RECRUITING
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Bryan Allen
NCT07193628 RECRUITING
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07223034 RECRUITING
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
NCT04319276 ACTIVE NOT RECRUITING
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Medical College of Wisconsin
NCT04555577 RECRUITING
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT07145112 RECRUITING
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
NCT04214392 ACTIVE NOT RECRUITING
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
City of Hope Medical Center
NCT02062827 ACTIVE NOT RECRUITING
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
University of Alabama at Birmingham
NCT03535350 ACTIVE NOT RECRUITING
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
NCT07179328 RECRUITING
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Sunnybrook Health Sciences Centre
NCT07141732 RECRUITING
Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy
Joint Stock Company European Medical Centre
NCT03223103 ACTIVE NOT RECRUITING
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Adilia Hormigo
NCT02208362 ACTIVE NOT RECRUITING
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
NCT04201873 ACTIVE NOT RECRUITING
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT05222802 ACTIVE NOT RECRUITING
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Katmai Pharmaceuticals Inc.
NCT06455189 NOT YET RECRUITING
Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
Case Comprehensive Cancer Center
NCT06614855 ACTIVE NOT RECRUITING
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
James Markert, MD
NCT03657576 ACTIVE NOT RECRUITING
Trial of C134 in Patients With Recurrent GBM
University of Alabama at Birmingham
NCT02974738 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT06773481 RECRUITING
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
NCT04477200 ACTIVE NOT RECRUITING
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
NCT04047706 ACTIVE NOT RECRUITING
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT06815029 RECRUITING
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
NCT06896110 ENROLLING BY INVITATION
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Andrew P. Groves
NCT05879367 RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
NCT06902350 RECRUITING
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT04323046 RECRUITING
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sabine Mueller, MD, PhD
NCT06632236 RECRUITING
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT05495295 RECRUITING
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Phost'In Therapeutics
NCT05769660 RECRUITING
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
BeyondBio Inc.
NCT06097975 RECRUITING
A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Universitair Ziekenhuis Brussel
NCT05698199 ACTIVE NOT RECRUITING
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Immunomic Therapeutics, Inc.
NCT05561374 ACTIVE NOT RECRUITING
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
NCT06585527 RECRUITING
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
NCT06616727 ENROLLING BY INVITATION
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Shanghai Simnova Biotechnology Co.,Ltd.
NCT04933422 NOT YET RECRUITING
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
Crimson Biopharm Inc.
NCT06524063 NOT YET RECRUITING
Targeted Survivin DC Cell Injection for the Treatment of GBM
Beijing Tricision Biotherapeutics Inc
NCT06418113 RECRUITING
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
Hospital San Carlos, Madrid
NCT06132438 NOT YET RECRUITING
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
Charlotte Lemech
NCT05363826 RECRUITING
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Photolitec LLC
NCT06860594 SUSPENDED
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
NCT05557292 TERMINATED
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Nicholas Butowski
NCT04968366 COMPLETED
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
Beijing Tiantan Hospital
NCT03451799 COMPLETED
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Jethro Hu
NCT07497373 COMPLETED
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma
Jecho Biopharmaceuticals Co., Ltd.
NCT06650605 COMPLETED
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
Theragnostics Ltd
NCT04019002 COMPLETED
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Susan Chang
NCT05139056 SUSPENDED
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT04716699 COMPLETED
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
University of California, Davis
NCT06665724 COMPLETED
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
NCT02669173 COMPLETED
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT05938387 COMPLETED
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CureVac
NCT03681028 COMPLETED
Feasibility of Individualized Therapy for Recurrent Glioblastoma
Jennifer Clarke
NCT06193174 TERMINATED
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
NCT06095375 COMPLETED
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
Istituto Oncologico Veneto IRCCS
NCT04295759 COMPLETED
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
NCT02709226 COMPLETED
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04474353 COMPLETED
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
NCT05977322 TERMINATED
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03224104 COMPLETED
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
European Organisation for Research and Treatment of Cancer - EORTC
NCT06806228 SUSPENDED
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Petrov, Andrey
NCT03107780 TERMINATED
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
NCT05341947 WITHDRAWN
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Jeremy Rudnick, M.D
NCT04982926 TERMINATED
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT03426891 COMPLETED
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03679754 COMPLETED
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Alaunos Therapeutics
NCT05376800 COMPLETED
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Boehringer Ingelheim
NCT03636477 COMPLETED
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
NCT04963413 TERMINATED
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
NCT06501911 WITHDRAWN
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
NCT03452930 COMPLETED
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
M.D. Anderson Cancer Center
NCT02766699 COMPLETED
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
Engeneic Pty Limited
NCT05187624 COMPLETED
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
Hoffmann-La Roche
NCT01430351 TERMINATED
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
NCT02186509 COMPLETED
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02026271 COMPLETED
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Alaunos Therapeutics
NCT04222309 SUSPENDED
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT02722512 TERMINATED
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
NCT05324501 TERMINATED
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Biodexa Pharmaceuticals
NCT04397679 TERMINATED
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
NCT02323880 COMPLETED
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT04842513 COMPLETED
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
University Hospital Tuebingen
NCT01849146 COMPLETED
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT01752491 COMPLETED
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Joseph J. Cullen, MD, FACS
NCT03232424 COMPLETED
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Hackensack Meridian Health
NCT02101905 COMPLETED
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT01811992 COMPLETED
Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma
University of Michigan Rogel Cancer Center
NCT05773664 WITHDRAWN
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
NCT03539731 TERMINATED
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Guido A. Davidzon, MD, SM
NCT04324840 TERMINATED
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
Celgene
NCT03493932 COMPLETED
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
National Institute of Neurological Disorders and Stroke (NINDS)
NCT04047303 TERMINATED
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
Celgene
NCT05538572 COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
NCT03250299 TERMINATED
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
NCT03434262 COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
NCT05304663 WITHDRAWN
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Philogen S.p.A.
NCT03043391 COMPLETED
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
NCT02133183 TERMINATED
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT05666349 WITHDRAWN
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
University College, London
NCT03705351 TERMINATED
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
NCT02869243 COMPLETED
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
Stemgen
NCT01922076 COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
National Cancer Institute (NCI)
NCT02457845 COMPLETED
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Gregory K. Friedman, MD
NCT04552886 COMPLETED
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
The Cooper Health System
NCT01421524 COMPLETED
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT02168270 TERMINATED
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
University of Nebraska
NCT02530502 TERMINATED
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02833701 TERMINATED
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
NCT03971734 TERMINATED
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02658981 COMPLETED
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02386826 COMPLETED
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
NCT04608812 TERMINATED
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OncoSynergy, Inc.
NCT02619864 COMPLETED
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
Canadian Cancer Trials Group
NCT04541225 TERMINATED
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
NCT02238496 COMPLETED
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Andrew B Lassman, MD
NCT03332355 TERMINATED
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Vanquish Oncology, Inc.
NCT02444546 COMPLETED
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
NCT03714334 TERMINATED
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
NCT04205357 COMPLETED
Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma
Haukeland University Hospital
NCT01700569 TERMINATED
Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
Institut Cancerologie de l'Ouest
NCT03867123 COMPLETED
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
NCT02664363 TERMINATED
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Daniel Landi
NCT03072134 COMPLETED
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
NCT03355794 COMPLETED
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT02311920 COMPLETED
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT04782609 TERMINATED
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Samus Therapeutics, Inc.
NCT01865162 COMPLETED
Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study
Mid-Atlantic Epilepsy and Sleep Center, LLC
NCT04200066 WITHDRAWN
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
NCT04489420 TERMINATED
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Celularity Incorporated
NCT05476341 COMPLETED
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT01808820 COMPLETED
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
Macarena De La Fuente, MD
NCT02644291 COMPLETED
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02864368 TERMINATED
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Eric Thompson, M.D.
NCT02808364 COMPLETED
Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
Guangdong 999 Brain Hospital
NCT02709616 COMPLETED
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
Guangdong 999 Brain Hospital
NCT02871843 COMPLETED
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
EpicentRx, Inc.
NCT01904123 COMPLETED
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT02270034 COMPLETED
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
NCT03341806 COMPLETED
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
Icahn School of Medicine at Mount Sinai
NCT02010606 COMPLETED
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Cedars-Sinai Medical Center
NCT03374943 COMPLETED
A Trial of KB004 in Patients With Glioblastoma
Olivia Newton-John Cancer Research Institute
NCT03422094 TERMINATED
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT02015819 COMPLETED
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT01353625 COMPLETED
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
NCT01723020 COMPLETED
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
Kartos Therapeutics, Inc.
NCT01851733 COMPLETED
MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
Washington University School of Medicine
NCT00747253 COMPLETED
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Monteris Medical
NCT03020602 COMPLETED
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Seema Nagpal
NCT04854044 WITHDRAWN
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT02903069 COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
NCT01180816 COMPLETED
Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
Northwell Health
NCT02255461 TERMINATED
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT03615404 COMPLETED
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Gary Archer Ph.D.
NCT01576666 COMPLETED
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01905228 COMPLETED
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Incuron
NCT01473901 COMPLETED
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novartis Pharmaceuticals
NCT01934361 COMPLETED
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis Pharmaceuticals
NCT03603379 COMPLETED
Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
University Hospital, Basel, Switzerland
NCT03619239 COMPLETED
Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
Genexine, Inc.
NCT04270461 WITHDRAWN
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
NCT03707457 TERMINATED
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02502708 COMPLETED
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
NewLink Genetics Corporation
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT04327011 TERMINATED
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Tocagen Inc.
NCT03573986 TERMINATED
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Abramson Cancer Center at Penn Medicine
NCT02378532 COMPLETED
The Addition of Chloroquine to Chemoradiation for Glioblastoma
Maastricht Radiation Oncology
NCT01392209 COMPLETED
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
NCT02017249 COMPLETED
Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
Inova Health Care Services
NCT02820584 COMPLETED
A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT03480867 WITHDRAWN
Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT03246113 TERMINATED
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
New York State Psychiatric Institute
NCT02202993 COMPLETED
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
Cavion, Inc.
NCT04002804 TERMINATED
Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT02337426 COMPLETED
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Virginia Commonwealth University
NCT01109095 COMPLETED
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Baylor College of Medicine
NCT00977431 COMPLETED
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
NCT00734526 TERMINATED
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT02853565 COMPLETED
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
CANbridge Life Sciences Ltd.
NCT00895960 TERMINATED
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
M.D. Anderson Cancer Center
NCT02728349 COMPLETED
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
NCT02718443 COMPLETED
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
Vaximm GmbH
NCT01967758 COMPLETED
Phase I Study of Safety and Immunogenicity of ADU-623
Providence Health & Services
NCT02176720 TERMINATED
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
The Methodist Hospital Research Institute
NCT02049489 COMPLETED
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Precision Life Sciences Group
NCT02149225 COMPLETED
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
NCT01103375 TERMINATED
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
NCT01151670 COMPLETED
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
Wake Forest University Health Sciences
NCT03275558 WITHDRAWN
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
NCT02197169 COMPLETED
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
DNAtrix, Inc.
NCT01985256 COMPLETED
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Tocagen Inc.
NCT01470794 COMPLETED
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Tocagen Inc.
NCT01156584 COMPLETED
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Tocagen Inc.
NCT00990496 TERMINATED
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
Milton S. Hershey Medical Center
NCT00841555 COMPLETED
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Ohio State University Comprehensive Cancer Center
NCT01234740 COMPLETED
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
City of Hope Medical Center
NCT02365662 TERMINATED
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
NCT02254954 TERMINATED
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
Actelion
NCT00693095 COMPLETED
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer
John Sampson
NCT01171469 COMPLETED
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Masonic Cancer Center, University of Minnesota
NCT01800695 COMPLETED
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
AbbVie
NCT02510950 TERMINATED
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT01339039 TERMINATED
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Patrick Y. Wen, MD
NCT01172964 COMPLETED
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
City of Hope Medical Center
NCT01956734 COMPLETED
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
NCT01975116 COMPLETED
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT01526837 TERMINATED
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Brain & Spine Surgeons of New York
NCT02648633 TERMINATED
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
University of Virginia
NCT01902771 TERMINATED
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
Edward Ziga
NCT01250470 COMPLETED
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Roswell Park Cancer Institute
NCT01148966 TERMINATED
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
University of Washington
NCT01238237 COMPLETED
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
NCT01308684 COMPLETED
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
Hoffmann-La Roche
NCT01547546 COMPLETED
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Genentech, Inc.
NCT01999270 COMPLETED
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
Washington University School of Medicine
NCT01522820 COMPLETED
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
NCT01588769 COMPLETED
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
CytoVac A/S
NCT01833273 COMPLETED
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Stony Brook University
NCT02031965 TERMINATED
Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
Pediatric Brain Tumor Consortium
NCT01144247 COMPLETED
Cellular Immunotherapy Study for Brain Cancer
Jonsson Comprehensive Cancer Center
NCT01499251 TERMINATED
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
Actelion
NCT01435395 COMPLETED
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Emory University
NCT00703859 WITHDRAWN
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
AHS Cancer Control Alberta
NCT01119599 COMPLETED
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
NCT01111097 COMPLETED
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
University of Florida
NCT01082926 COMPLETED
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
NCT01861990 WITHDRAWN
Valproic Acid in Childhood Progressive Brain Tumors
Medical University of South Carolina
NCT00821080 COMPLETED
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Massachusetts General Hospital
NCT01122888 TERMINATED
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT00968240 COMPLETED
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Northwell Health
NCT01317212 WITHDRAWN
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
North Bristol NHS Trust
NCT00979862 COMPLETED
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT00694837 COMPLETED
Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma
Maastricht Radiation Oncology
NCT00734682 COMPLETED
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
University of California, San Francisco
NCT01131234 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01378481 TERMINATED
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
NCT00960492 COMPLETED
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Exelixis
NCT00650923 COMPLETED
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
NCT01403285 TERMINATED
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Immatics Biotechnologies GmbH
NCT01854099 WITHDRAWN
Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens
University of Florida
NCT00762255 COMPLETED
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT00704080 COMPLETED
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
Sanofi
NCT00613223 COMPLETED
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Annick Desjardins
NCT01269411 TERMINATED
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
National Cancer Institute (NCI)
NCT00734864 WITHDRAWN
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
Annick Desjardins
NCT01043536 COMPLETED
Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults
Centre Georges Francois Leclerc
NCT01294735 COMPLETED
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Merck Sharp & Dohme LLC
NCT01240460 COMPLETED
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Sanofi
NCT01441388 WITHDRAWN
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
NCT00904852 WITHDRAWN
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
NCT07546669 NOT YET RECRUITING
Efficacy of Zoster Vaccination in Glioblastoma Patients
University Hospital, Essen
NCT05342883 ACTIVE NOT RECRUITING
GammaTile and Stupp in Newly Diagnosed GBM
GT Medical Technologies, Inc.
NCT05235737 RECRUITING
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Medical University of Silesia
NCT06625047 COMPLETED
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
NCT05900908 WITHDRAWN
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
GT Medical Technologies, Inc.
NCT00686725 COMPLETED
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Full Glioblastoma Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only